Biohaven Ltd. Investment Income, Net
Biohaven Ltd. (BHVN) reported Investment Income, Net of $2.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-10
- Biohaven Ltd. investment income, net for the quarter ending 2026-06-30 was $2.68M, a 35.40% decline year-over-year.
- Biohaven Ltd. investment income, net for the quarter ending 2026-03-31 was $3.25M, a 22.73% decline year-over-year.
- Biohaven Ltd. investment income, net for the quarter ending 2025-12-31 was $2.82M, a 55.19% decline year-over-year.
- Biohaven Ltd. investment income, net for the quarter ending 2025-09-30 was $3.41M, a 39.62% decline year-over-year.
- Biohaven Ltd. investment income, net for fiscal 2025 was $14.59M, a 31.63% decline from fiscal 2024.
- Biohaven Ltd. investment income, net for fiscal 2024 was $21.33M, a 20.63% increase from fiscal 2023.
- Biohaven Ltd. investment income, net for fiscal 2023 was $17.69M, a 451.31% increase from fiscal 2022.
- Biohaven Ltd. investment income, net for fiscal 2022 was $3.21M.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.68M 10-Q · filed 2026-08-10 | $5.93M 10-Q · filed 2026-08-10 | $8.75M derived: sum of 3 quarters · filed 2026-08-10 | $12.16M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $3.25M 10-Q · filed 2026-05-04 | $6.07M derived: sum of 2 quarters · filed 2026-05-04 | $9.48M derived: sum of 3 quarters · filed 2026-05-04 | $13.63M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.23M derived: sum of 2 quarters · filed 2026-03-02 | $10.38M derived: sum of 3 quarters · filed 2026-08-10 | $14.59M 10-K · filed 2026-03-02 |
| 2025-09-30 | $3.41M 10-Q · filed 2025-11-10 | $7.56M derived: sum of 2 quarters · filed 2026-08-10 | $11.77M 10-Q · filed 2025-11-10 | $18.05M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $4.15M 10-Q · filed 2026-08-10 | $8.36M 10-Q · filed 2026-08-10 | $14.64M derived: sum of 3 quarters · filed 2026-08-10 | $20.29M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $4.21M 10-Q · filed 2026-05-04 | $10.49M derived: sum of 2 quarters · filed 2026-05-04 | $16.14M derived: sum of 3 quarters · filed 2026-05-04 | $21.24M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.93M derived: sum of 2 quarters · filed 2026-03-02 | $17.03M derived: sum of 3 quarters · filed 2026-03-02 | $21.33M 10-K · filed 2026-03-02 |
| 2024-09-30 | $5.65M 10-Q · filed 2025-11-10 | $10.75M derived: sum of 2 quarters · filed 2025-11-10 | $15.05M 10-Q · filed 2025-11-10 | $20.75M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $5.10M 10-Q · filed 2025-08-11 | $9.40M 10-Q · filed 2025-08-11 | $15.10M derived: sum of 3 quarters · filed 2026-03-02 | $18.86M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $4.30M 10-Q · filed 2025-05-12 | $10.00M derived: sum of 2 quarters · filed 2026-03-02 | $13.76M derived: sum of 3 quarters · filed 2026-03-02 | $17.86M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.46M derived: sum of 2 quarters · filed 2026-03-02 | $13.56M derived: sum of 3 quarters · filed 2026-03-02 | $17.69M 10-K · filed 2026-03-02 |
| 2023-09-30 | $3.77M 10-Q · filed 2024-11-12 | $7.86M derived: sum of 2 quarters · filed 2024-11-12 | $11.99M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $4.10M 10-Q · filed 2024-08-09 | $8.22M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $4.10M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $3.21M 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |